Medical devices major,
St. Jude Medical Inc.
) has launched its latest ILUMIEN OPTIS System for the first time
in Japan. This imaging technology is an advanced version of the
company's Ilumien System from the cardiovascular products
The ILUMIEN OPTIS System, featuring the unique Fractional Flow
Reserve (FFR) and Optical Coherence Tomography (OCT) platforms,
provides cardiologists with comprehensive information to take
patient-specific stenting decisions, resulting in better
treatment outcomes. Additionally, the device features a
three-dimensional vessel reconstruction technology coupled with a
unique stent planning software tool, which further enhances
diagnostics and treatment strategies.
Japan is a global leader in imaging technology utilization,
according to STJ. About 245,000 Percutaneous Coronary
Intervention (PCI) procedures are performed every year in Japan,
out of which, 80% use imaging technology. The Japanese language
option available with the ILUMIEN OPTIS makes it user-friendly
for the target population.
In 2012, St. Jude's net sales in Japan increased by 10% to
$456 million. The termination of a distribution contract in Japan
adversely affected 2012 vascular product net sales by 7% but
solid sales and continued market penetration of the Ilumien
platform partially offset the decline. Barring the impact of the
contract termination, the company's cardiovascular revenues grew
6% in 2012.
St. Jude expects the cardiovascular business to grow 6%-9% on
a constant currency basis in 2013 on the back of a change in
sales mix from declining legacy products to high growth
offerings. We believe that the launch of the new ILUMIEN OPTIS
device in Japan should add to total sales, given its cutting-edge
St. Jude has a Zacks Rank #3 (Hold). The company's
fourth-quarter adjusted earnings per share of 92 cents (up 7%
year-over-year) topped the Zacks Consensus Estimate by 2
While we remain on the sidelines regarding St. Jude due to
softness in the core Cardiac Rhythm Management ("CRM") business,
medical products companies such as
) appear impressive. Nuvasive carries a Zacks Rank #1 (Strong
Buy) and the other two carry a Zacks Rank #2 (Buy).
ABAXIS INC (ABAX): Free Stock Analysis Report
CAREFUSION CORP (CFN): Free Stock Analysis
NUVASIVE INC (NUVA): Free Stock Analysis
ST JUDE MEDICAL (STJ): Free Stock Analysis
To read this article on Zacks.com click here.